Half a century of newborn screening in Spain: Evolution of ethical, legal and social issues (ELSIs). Part I, ethical issues

被引:0
作者
Pampols Ros, Teresa [1 ,10 ,11 ]
Perez Aytes, Antonio [2 ,10 ]
Garcia Sagredo, Jose Miguel [3 ,10 ]
Diaz de Bustamante, Aranzazu [4 ,10 ]
Martin Arribas, Concepcion [5 ,11 ]
Garcia Lopez, Fernando Jose [6 ,11 ]
Nicolas Jimenez, Pilar [7 ,11 ]
Dulin Iniguez, Elena [8 ]
Labrador Canadas, Ma Vicenta [9 ]
机构
[1] Hosp Clin Barcelona, Secc Errores Congenitos Metab IBC, Serv Bioquim & Genet Mol, Barcelona, Spain
[2] Hosp La Fe, Inst Invest Sanitaria, Grp Invest Perinatol, Valencia, Spain
[3] Univ Alcala, Fac Med, Madrid, Spain
[4] Hosp Univ Mostoles, Unidad Genet, Madrid, Spain
[5] Inst Salud Carlos III, Subdirecc Gen Invest Terapia Celular & Med Regene, Madrid, Spain
[6] Inst Salud Carlos III, Ctr Nacl Epidemiol, Madrid, Spain
[7] Univ Basque Country, Catedra Derecho & Genoma Humanao, Pais Vasco, Spain
[8] Minist Sanidad, Ponencia Cribado Neonatal Direcc Gen Salud Publ, Madrid, Spain
[9] Minist Sanidad, Unidad Prowamas Cribado, Madrid, Spain
[10] Asociac Espanola Genet Humana AEGH, Comis Et, Madrid, Spain
[11] Inst Salud Carlos III, Com Et Invest CEI, Madrid, Spain
来源
REVISTA ESPANOLA DE SALUD PUBLICA | 2021年 / 95卷
关键词
Newborn screening; Blood spot screening; Genetic screening; Rare disease screening; Ethical issues in newborn screening; Public health ethics; Wilson-Jungner criteria; Ethical; legal and social issues (ELSIEs); PUBLIC-HEALTH; BLOOD SPOTS; CRITERIA; PRINCIPLES; FRAMEWORK; JUNGNER; BENEFIT; WILSON;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Newborn screening for treatable diseases began in Spain in 1968. During this half century important changes political, social and technologic have occurred. Present work divided in three parts analyzes the evolution of ethical, legal and social issues (ELSIs), respectively Part I, Pan II and Part III. Part I, ethical issues is aimed to the consideration of principles of biomedical and public health ethics applied to newborn screening programs in relationship with its technical characteristics which are very relevant for ethical deliberation: newborn screening is a genetic screening; only a small number of newborns suffers disease included in the program and therefore will receive benefits; screening applies to asymptomatic and vulnerable newborns that cannot exerts his/her autonomy and therefore must be protected; evaluation of results is challenging; as any public health intervention may have adverse consequences. Chronological evolution states a first period 1968-2000 beginning with the principles of Wilson - Jungner, the first paper containing ethical principles that can be applied to newborn screening, introducing decision criteria and good practices in public health policies. A second period 2000-2010 markedly influenced by the emergency of tandem mass spectrometry that promotes a sudden expansion of programs and the consequent ethic debate, Wilson-Jungner principles are reviewed and appear relevant ethical documents in USA, Europe and also in Spain with the first's papers on ethical recommendations for screening programs. A third period 2000-2019 examines the incorporation of new criteria in programs implementation and the continuous technological challenges with newborn genome sequencing already in the horizon. It will be very important for the future of the newborn screening programs the development of ethical, legal and social issues in parallel with technological challenges. And that health authorities places diseases and not technologies as central subject, acting in children best interest, looking for a positive balance of benefits/ risks and observing the relevant and well acknowledged principles for genetic screening of proportionality, respect for autonomy and justice.
引用
收藏
页数:22
相关论文
共 73 条
  • [11] [Anonymous], CRITERIA APPRAISING
  • [12] [Anonymous], 2012, REPORT PRACTICES NEW
  • [13] Arena J, 2008, B REAL PATRONATO PRE
  • [14] New born screening for developmental disabilities: Reframing presumptive benefit
    Bailey, DB
    Skinner, D
    Warren, SF
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2005, 95 (11) : 1889 - 1893
  • [15] Baily MA, 2008, HASTINGS CENT REP, V38, P23
  • [16] Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme
    Bessey, Alice
    Chilcott, James B.
    Leaviss, Joanna
    Sutton, Anthea
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2018, 13
  • [17] THE EXPANSION OF NEWBORN SCREENING: IS REPRODUCTIVE BENEFIT AN APPROPRIATE PURSUIT?
    Bombard, Yvonne
    Miller, Fiona A.
    Hayeems, Robin Z.
    Avard, Denise
    Knoppers, Bartha M.
    Cornel, Martina C.
    Borry, Pascal
    [J]. NATURE REVIEWS GENETICS, 2009, 10 (10) : 666 - 667
  • [18] Borry P, 2009, EUR J HUM GENET, V17, P711, DOI [10.1038/ejhg.2009.25, 10.1038/ejhg.2009.26]
  • [19] Newborn screening technology: Proceed with caution
    Botkin, JR
    Clayton, EW
    Fost, NC
    Burke, W
    Murray, TH
    Baily, MA
    Wilfond, B
    Berg, A
    Ross, LF
    [J]. PEDIATRICS, 2006, 117 (05) : 1793 - 1799
  • [20] Burgard P, 2011, Short executive summary of the report on the practices of newborn screening for rare disorders implemented in Member States of the European Union, candidate, potential candidate and EFTA countries